the aid library

LIST OPTIONS

Filter

8761

Global framework for the response to malaria in urban areas

World Health Organization WHO (2022) C_WHO

Cities are uniquely positioned to understand local needs and respond rapidly to changing conditions to safeguard health. These changes require strong city leadership to implement multisectoral, health-relevant policies and public services that engage communities. The response to malaria must be an i... more

Download (115)

View PDF (201)

Global Programme to Eliminate Lymphatic Filariasis

World Health Organization WHO (2013) C_WHO

The document explains why vector control is important in national programmes and describes the preparation of a tailor-made vector control plan for national programmes. It outlines entomological procedures for regular and specific vector control and how data should be analysed for better overall und... more

Traditions and Opportunities - A Toolkit for GBV Programs to Engage Community Leaders in Humanitarian Settings [EN/AR]

International Medical Corps (IMC) (2021) C2

Travailler avec les dirigeants communautaires pour lutter contre la VBG est une très bonne et prometteuse approche, car les dirigeants communautaires sont les gardiens de toutes nos croyances et coutumes. Étant donné que la VBG est enracinée dans les croyances et les coutumes, essayer de s�... more

External Link

Trichiasis surgery for trachoma Second Edition

Merbs, S.; Resnikoff, S.; Kello, A. World Health Organization WHO (2015) C_WHO

This manual is designed to provide specific information for trachomatous trichiasis (TT) trainers who are training others to undertake surgery for entropion trachomatous trichiasis (TT). Other approaches are not addressed. The manual is divided into two parts. The first part covers specifics designe... more

Download (109)

View PDF (139)

Target product profile for a test for rhodesiense human African trypanosomiasis diagnosis usable in peripheral health facilities

World Health Organization WHO (2021) C_WHO

The development of this target product profile (TPP) was led by the WHO Department of Control of Ne- glected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was... more

External Link

Ethiopia - National Cholera Control Operational Plan 2022/23

Government of Ethiopia (2023) CC

Cholera is a diarrheal disease caused by the bacterium Vibrio cholera. The infection primarily spreads through contaminated water and food. Symptoms include the onset of acute diarrhea and/or vomiting, muscle cramps, and body weakness. If untreated, the infection can result in rapid dehydration and ... more

External Link

Protection risk analysis for CVA in the Ukraine response

Protection Cluster; Save the Children; Women's Refugee Commission (2023) CC

Over the past few weeks, members of the C4PTF for the Ukraine Response have started mapping the different protection risks that refugees and IDPs are facing in Ukraine and while travelling. This work has been notably built upon efforts conducted in each country, such as the GBV Risk Analysis for CVA... more

Download (165)

View PDF (178)

A clinical case definition for post Covid-19 condition in children and adolescents by expert consensus

World Health Organisation (WHO) (2023) C_WHO

Background: The World Health Organization (WHO) published a clinical case definition of post COVID-19 condition, by a Delphi consensus, on 6 October 2021. That process concluded that a separate definition may be applicable for children. It is important to understand the frequency, characteristics ... more

External Link

One Health Joint Plan of Action (2022-2026)

World Organisation for Animal Health Food and Agriculture Organization of the United Nations; United Nations Enviroment Programme; Wolrd Health Organization; World Organisation for Animal Health (2022) C_WHO

The desired impact of the OH JPA is a world better able to prevent, predict, detect and respond to health threats and improve the health of humans, animals, plants and the environment while contributing to sustainable development. The OH JPA aims to work towards this vision in the following way: ... more

Download (163)

View PDF (199)

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

External Link

Minimum technical standards and recommendations for reproductive, maternal, newborn and child health care for emergency medical teams

World Health Organization WHO; Institutional research information system iris (2021) C_WHO

World Health Organization. (‎2021)‎. Minimum technical standards and recommendations for reproductive, maternal, newborn and child health care for emergency medical teams. World Health Organization.

Download (211)

View PDF (203)

Forests and Trees for Human Health: Pathways, Impacts, Challenges and Response Options

Cecil Konijnendijk, Dikshya Devkota, Stephanie Mansourian & Christoph Wildburger (eds.) International Union of Forest Research Organizations (IUFRO) (2023) C2

Forests, trees and green spaces, hereinafter ‘forests and trees’ for short, provide multiple goods and services that contribute to human health. These include medicines, nutritious foods and other non-wood forest products (NWFPs). Globally, at least 3.5 billion people use NWFPs, including medici... more

External Link

Climate Change and Chagas Disease in the americas: A qualitative systematic review

Graves B.N. (2019) C2

Chagas disease is currently endemic and also predicted to be at increased transmission risk under future climate change scenarios. Similarly, an expansion of areas in the United States at increased risk for Chagas disease transmission is also expected over the next several decades under climate chan... more

Download (168)

View PDF (184)

“Crafting the mosaic” A framework for resilient surveillance for respiratory viruses of epidemic and pandemic potentia

World Health Organisation (WHO) (2023) C_WHO

It is impossible to address the many complex needs of respiratory virus surveillance with a single surveillance system. Multiple systems, investigations and studies must each be fit-for-purpose to specific priority surveillance objectives, and only together can they provide essential information to ... more

External Link

Integration of Water, Sanitation, and Hygiene for the Prevention and Control of Neglected Tropical Diseases: A Rationale for Inter-Sectoral Collaboration

Freeman, M.C.; Ogden, S.; Jacobson, J. et al PLoS Neglected Tropical Diseases (2013) C2

https://doi.org/10.1371/journal.pntd.0002439 South Sudan has a high burden – among the highest in sub-Saharan Africa – of neglected tropical diseases (NTDs). This adversely affects the health and social and economic well-being of people in the country. The prevention, control and eventual elim... more

Download (121)

View PDF (171)

Financing for Sustainable Development Report 2020

Inter-agency Task Force on Financing for Development United Nations (UN) (2020) CC

The 2020 Financing for Sustainable Development Report, the fifth report of the Inter-agency Task Force on Financing for Development, provides a comprehensive assessment of the state of sustainable finance. Prepared by more than 60 agencies of the United Nations system and partner international organ... more

Download (137)

View PDF (139)

Working Paper 46 - Aid, China, and Growth: Evidence from a New Global Development Finance Dataset

Dreher, A.; A. Fuchs; B. Parks et al. AidData at William & Mary (2017) CC

This paper introduces a new dataset of official financing—including foreign aid and other forms of concessional and non-concessional state financing—from China to 138 countries between 2000 and 2014. We use these data to investigate whether and to what extent Chinese aid affects economic growth ... more

Download (142)

View PDF (151)

First, Do No Harm - Examining the impact of the IFC’s support to private healthcare in India

Anjela Taneja and Amitabha Sarkar Oxfam International (2023) CC

This report examines the support to private healthcare provision in India by the World Bank’s private sector arm, the International Finance Corporation (IFC). Despite supporting private healthcare in the country since 1997, no healthcare results for lending and investments have been disclosed sinc... more

Download (167)

View PDF (148)

Public health resource pack for countries experiencing outbreaks of influenza in animals: revised guidance

World Health Organisation (WHO) (2023) C_WHO

This resource pack was developed for the country offices of the World Health Organization and national Public Health institutions, as an overview of the key information needed for advising their Member States in response to questions raised on human health due to influenza outbreaks or detections in... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more